Document Type

DNP Project

Department

School of Nursing

Date of Degree

Spring 2018

Degree

Doctor of Nursing Practice (DNP)

Primary Advisor

Qiuping (Pearl) Zhou, PhD, RN; Dennis D. Hickstein, MD; Nirali N. Shah, MD, MHSc

Keywords

GATA2 deficiency, Dedicator-of-Cytokinesis-8 (DOCK8) deficiency, allogeneic hematopoietic stem cell transplant (HSCT)

Abstract

Background/Purpose: GATA2 and Dedicator-of-Cytokinesis-8 (DOCK8) deficiencies are two recently described genetic immunodeficiency diseases for which allogeneic hematopoietic stem cell transplant (HSCT) represents the only definitive therapy. The patient characteristics and HSCT variables that relate to the outcomes in these two diseases following HSCT remain unclear. Therefore, we described these variables in these two patient populations and explored their relationships with HSCT outcomes.

Methods: Data were obtained from retrospective chart reviews of all patients with GATA2 deficiency and DOCK8 deficiency who underwent HSCT on clinical research protocols at the National Cancer Institute. The outcomes included overall and disease-free survival status, graftversus-host disease (GVHD), and HSCT complications.

Results: Of the 51 patients who underwent HSCT, 37 had GATA2 deficiency and 24 had DOCK8 deficiency. On the GATA2 protocols, 28 of 37 patients (75%) were alive at the time of the review and all had reversal of the disease phenotype. GATA2 deficiency patients had a mean of 2.2 (SD=1.2) and 0.8 (SD=1.1) life-threatening infections pre-HSCT and post-HSCT, respectively. Of the 24 DOCK8 patients on protocol 19 (79.2%) were alive at the time of review and all had correction of their underlying disease. The DOCK8 patients had a mean of 1.8 (SD=0.7), and 0.9 (SD=0.7) life-threatening infections pre-HSCT and post-HSCT, respectively.

Conclusions & Implications: This study fills a gap in the scientific literature by providing data on patient characteristics, HSCT factors, treatment access, and the clinical outcomes for two the recently described primary genetic immunodeficiency diseases. Our results indicate that patients, with GATA2 or DOCK8 deficiencies undergoing HSCT prior to the development of lifethreatening infections, end-organ damage, or myeloid transformation, have favorable clinical outcomes with correction of the underlying immunodeficiency. This study provides information for health care providers caring for these patients, on the effect of the social determinants and prognostic factors on successful HSCT.

Open Access

1

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.